AMRN - アマリン (Amarin Corporation plc) アマリン

 AMRNのチャート


 AMRNの企業情報

symbol AMRN
会社名 Amarin Corp Plc (アマリン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アマリン(Amarin Corporation plc)は心血管疾患の治療を中心とする脂質科学の専門知識を持つ後期臨床試験段階のバイオ医薬品会社。同社の製品候補「AMR101」は超高純度オメガ3脂肪酸である。同社はトリグリセリド値の高い患者または高トリグリセリド血症患者を治療するための薬品「AMR101」を開発している。平成23年9月、同社は米国食品医薬品局(FDA)に新薬承認申請(NDA)を提出した。平成23年12月、同社は「REDUCE-IT」というタイトルが付けられた「AMR101」の心血管成果試験(イコサペンタエン酸(EPA)及び心血管事故の減少という介入試験)での患者への投薬を開始した。   アマリンは英国のバイオ医薬品メ―カ―。循環器疾患の治療に焦点を当てた治療薬の研究、開発、商業化に従事。主力製品の「Vascepa」カプセルは、重度の高トリグリセリド血症の成人患者向けの治療薬で、米国食品医薬品局(FDA)の承認を取得。エイコサベンタエン酸のエチルエステルを高純度で含む。本社はアイルランド。   Amarin is a rapidly growing, innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From its scientific research foundation to its focus on clinical trials, and now its commercial expansion, it is evolving and growing. In 2009, Amarin had fewer than twenty employees. Today, with offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland, Amarin has approximately 1,000 employees and commercial partners and suppliers around the world. It is committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.
本社所在地 2 Pembroke House Upper Pembroke Street 28-32 Dublin Ballsbridge 2 IRL
代表者氏名 Lars G. Ekman ラース・エックマン
代表者役職名 Independent Chairman of the Board
電話番号 +353 1-669-9020
設立年月日 32568
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 241人
url www.amarincorp.com
nasdaq_url https://www.nasdaq.com/symbol/amrn
adr_tso 291562458
EBITDA EBITDA(百万ドル) -69.12400
終値(lastsale) 18.9
時価総額(marketcap) 5510530456.2
時価総額 時価総額(百万ドル) 5215.741
売上高 売上高(百万ドル) 197.78800
企業価値(EV) 企業価値(EV)(百万ドル) 5254.872
当期純利益 当期純利益(百万ドル) -84.19700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Amarin Corporation plc (ADR) revenues increased 21% to $96.6M. Net loss increased 69% to $58.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling/General/Admin. Expense increase of 43% to $71.7M (expense) Co-promotion fees increase from $5.2M to $19.4M (expense).

 AMRNのテクニカル分析


 AMRNのニュース

   Pharma company Amarin has a key asset and a big decision. How Sarissa Capital can help it move forward  2022/01/29 13:45:55 CNBC
Activist fund Sarissa brings extensive knowledge and deep contacts in the health-care space, which could come in handy at Amarin.
   Amarin (AMRN) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference  2022/01/12 21:12:29 Seeking Alpha
   Amarin Corporation plc (AMRN) Fell Out Of Favor With Hedge Funds?  2022/01/12 17:11:18 Insider Monkey
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade.
   Amarin Corporation plc (AMRN) CEO Karim Mikhail Presents at 40th Annual J.P. Morgan Healthcare Conference (Transcript)  2022/01/11 16:37:02 Seeking Alpha
   Amarin sees Q4 and FY21 revenue below consensus; shares down 3% (NASDAQ:AMRN)  2022/01/10 12:57:04 Seeking Alpha
Amarin (AMRN) provides a business update, including preliminary full-year 2021 revenue results. Q4 and FY 2021 total net revenues are estimated to be ~$140M (consensus $156.02M)
   Amarin (AMRN) Investor Presentation - Slideshow  2021/10/01 19:42:29 Seeking Alpha
   Amarin Corporation plc (AMRN) Management Presents at Cantor Fitzgerald Global Healthcare 2021 Conference (Transcript)  2021/09/28 20:41:05 Seeking Alpha
   Amarin: Maximum Optimism  2021/09/22 13:34:46 Seeking Alpha
   Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S.  2021/09/22 13:15:00 Intrado Digital Media
Enables Amarin to Drive Additional Demand, Improve Patient Access & Education and Secure Proper Fulfillment and Reimbursement Enables Amarin to Drive Additional Demand, Improve Patient Access & Education and Secure Proper Fulfillment and Reimbursement
   Surprising stocks: Amarin Corporation plc (NASDAQ:AMRN -1.55%), Oasis Petroleum Inc. (NASDAQ:OAS -0.97%)  2021/09/17 23:51:29 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Surprising stocks: Amarin Corporation plc (NASDAQ:AMRN -1.55%), Oasis Petroleum Inc. (NASDAQ:OAS -0.97%) appeared first on Stocks Equity .
   Amarin Corporation's (AMRN) CEO John Thero on Jefferies Virtual Healthcare Conference - Transcript  2021/06/02 17:45:03 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アマリン AMRN Amarin Corporation plc)

 twitter  (公式ツイッターやCEOツイッターなど)